captur
enzymeenhanc
chemiluminesc
immunoassay
eclia
base
three
specif
monoclon
antibodi
detect
nucleocapsid
n
protein
sever
acut
respiratori
syndrom
sar
associ
coronaviru
sarscov
serial
serum
sampl
sar
patient
develop
antisarscov
igg
viral
rna
also
detect
sera
elisa
rtpcr
respect
first
day
onset
antisarscov
igg
sarscov
rna
n
protein
detect
patient
sera
respect
detect
rate
n
protein
day
diseas
still
significantli
higher
antisarscov
igg
sarscov
rna
data
demonstr
detect
n
protein
captur
eclia
appear
use
detect
viral
maker
rapid
diagnosi
sar
patient
sever
acut
respiratori
syndrom
sar
infecti
diseas
occur
firstli
guangdong
provinc
southern
part
china
novemb
caus
outbreak
countri
area
spring
clinic
case
death
result
overal
mortal
rate
outbreak
contain
midjuli
three
event
laboratoryassoci
infect
caus
total
clinic
sar
case
normil
vogel
normil
normil
guangdong
four
clinic
sar
case
occur
sporad
without
contact
histori
decemb
januari
liang
et
al
hand
origin
etiolog
agent
sar
sarscov
remain
elus
although
sarscovlik
viru
isol
civet
cat
fact
initi
clinic
sar
case
occur
independ
without
contact
histori
differ
area
guangdong
find
viral
sequenc
isol
patient
group
differ
subtyp
cluster
chines
sar
molecular
epidemiolog
consortium
suggest
patient
china
infect
sarscov
multipl
infecti
sourc
rather
singl
sourc
therefor
sar
may
recurr
human
be
sarscov
envelop
singlestrand
positivesens
rna
viru
classifi
new
group
coronavirida
famili
viral
genom
approxim
kb
length
open
read
frame
sarscov
contain
four
major
structur
protein
includ
spike
membran
small
envelop
e
nucleocapsid
n
marra
et
al
rota
et
al
protein
mediat
attach
viru
cellular
receptor
li
et
al
viru
entri
fusion
cell
membran
hofmann
et
al
yang
et
al
e
protein
integr
membran
protein
form
minimum
protein
unit
viru
assembl
n
protein
extens
phosphoryl
highli
basic
protein
interact
viral
rna
make
viral
core
nucleocapsid
lai
diagnosi
sar
depend
basic
upon
detect
sarscov
rna
rtpcr
andor
test
specif
antibodi
direct
sarscov
assay
base
cultur
viru
recombin
viral
antigen
although
rtpcr
reliabl
techniqu
diagnosi
sar
earli
phase
detect
rate
probabl
sar
wu
et
al
antibodi
direct
sarscov
examin
immunofluoresc
assay
immunochromatograph
test
enzymelink
immunosorb
assay
elisa
western
blot
detect
case
wu
et
al
guan
et
al
et
al
li
et
al
howev
take
week
onset
measur
specif
antibodi
develop
therefor
detect
antisarscov
igg
practic
strategi
rapid
diagnosi
sinc
sarscov
highli
contagi
diseas
sever
high
mortal
rate
rapid
diagnosi
sar
signific
import
treat
patient
prevent
spread
diseas
recent
assay
base
monoclon
antibodi
che
et
al
che
et
al
polyclon
antibodi
lau
et
al
direct
n
protein
develop
detect
n
protein
sarscov
serum
sampl
clinic
specimen
present
studi
captur
eclia
develop
base
three
monoclon
antibodi
direct
n
protein
sarscov
n
protein
longitudin
serum
sampl
sar
patient
detect
method
antisarscov
igg
sarscov
rna
also
detect
serial
sera
probabl
sar
patient
use
n
protein
sarscov
rna
antisarscov
igg
identifi
infect
earli
phase
evalu
three
hundr
thirtysix
serial
serum
sampl
collect
probabl
sar
patient
xiongk
hospit
beij
use
studi
probabl
patient
femal
male
patient
age
year
patient
clinic
featur
probabl
case
sar
defin
addit
serum
sampl
close
contact
develop
symptom
sampl
healthi
blood
donor
also
use
studi
studi
review
clinic
radiolog
laboratori
featur
patient
approv
ethic
committe
beij
xiongk
hospit
antisarscov
igg
detect
use
commerci
indirect
elisa
kit
bdigbi
biotech
beij
develop
base
sarscov
lysat
coat
antigen
briefli
lwell
serum
dilut
tween
pb
pbst
ad
viral
proteinco
plate
incub
c
min
follow
five
wash
pbst
lwell
peroxidaseconjug
mous
antihuman
igg
fcgamma
specif
antibodi
dilut
pbst
ad
follow
incub
c
min
plate
wash
lwell
substrat
tetramethylbenzidin
solut
ad
incub
room
temperatur
min
color
develop
stop
ad
h
optic
densiti
od
nm
measur
elisa
reader
blank
neg
posit
control
alway
includ
plate
cutoff
valu
calcul
mean
plu
normal
serum
control
total
rna
l
serum
sar
patient
extract
use
qiaamp
viru
rna
mini
kit
qiagen
extract
rna
subject
singl
step
rtpcr
follow
second
round
pcr
amplifi
target
viral
sequenc
essenti
way
describ
elsewher
yam
et
al
result
product
electrophores
agaros
gel
trisbor
buffer
target
band
visual
stain
ethidium
bromid
posit
neg
control
includ
run
precaut
prevent
crosscontamin
observ
captur
eclia
develop
collabor
beij
weixiao
biotech
detect
n
antigen
sarscov
sera
sar
patient
base
assay
develop
che
et
al
modif
microtit
plate
coat
lwell
mixtur
three
antin
protein
monoclon
antibodi
kindli
provid
dr
che
zhujiang
hospit
south
medic
univers
china
che
et
al
concentr
gml
carbonatebicarbon
buffer
ph
incub
c
overnight
plate
wash
five
time
pbst
block
l
casein
pbst
h
c
follow
five
wash
pbst
l
serum
dilut
twofold
pbst
ad
well
incub
c
h
five
wash
lwell
peroxidaseconjug
rabbit
antisarscov
polyclon
antibodi
beij
weixiao
biotech
dilut
pbst
ad
incub
c
h
five
wash
lwell
chemiluminesc
substrat
solut
ad
incub
min
room
temperatur
final
rel
luminesc
valu
rlv
read
micropl
singl
photon
counter
beij
weixiao
biotech
cutoff
valu
time
mean
rlv
neg
control
serum
sampl
probabl
sar
patient
test
antisarscov
igg
indirect
elisa
develop
base
cultur
sarscov
lysat
coat
antigen
shown
tabl
first
day
diseas
antisarscov
detect
three
patient
thereaft
patient
seroconvert
posit
rate
antisarscov
igg
increas
day
onset
day
patient
detect
specif
antibodi
day
onset
observ
least
long
antibodi
last
antisarscov
subsequ
sera
collect
afterward
patient
also
measur
sera
still
posit
antisarscov
indic
antisarscov
igg
last
least
day
onset
addit
result
also
show
concentr
antisarscov
igg
increas
convalesc
phase
sinc
od
valu
convalesc
sera
higher
acut
sampl
data
shown
hand
serum
sampl
subject
close
contact
probabl
sar
patient
develop
symptom
neg
antisarscov
igg
similarli
none
serum
sampl
healthi
blood
donor
collect
period
sar
outbreak
posit
antibodi
total
serum
sampl
collect
differ
phase
diseas
sar
patient
test
viral
rna
sarscov
rtpcr
tabl
show
posit
rate
viral
rna
circul
variou
stage
diseas
first
day
six
patient
posit
sarscov
rna
subsequ
phase
posit
rate
viral
rna
n
protein
sarscov
test
total
sera
sar
patient
antigencaptur
eclia
base
monoclon
antibodi
direct
n
protein
sarscov
shown
tabl
n
protein
detect
nine
ten
patient
first
day
onset
posit
rate
remain
day
hand
first
day
sarscov
rna
detect
four
ten
patient
posit
rate
day
tabl
n
antigen
still
remain
posit
eight
one
sampl
day
day
diseas
respect
howev
sarscov
rna
becam
neg
period
n
protein
detect
serum
sampl
collect
day
onset
antisarscov
igg
posit
serum
sampl
n
protein
detect
sera
normal
blood
donor
data
shown
studi
antisarscov
igg
sarscov
rna
n
protein
examin
consecut
serum
sampl
probabl
sar
patient
detect
n
protein
sarscov
serum
sampl
eclia
appear
superior
detect
viral
rna
rtpcr
rapid
diagnosi
sar
patient
probabl
case
studi
confirm
retrospect
infect
sarscov
detect
antisarscov
igg
convalesc
serum
sampl
elisa
antisarscov
igg
use
studi
shown
highli
specif
li
et
al
chen
et
al
find
none
sera
healthi
blood
donor
posit
antisarscov
also
indic
antibodi
detect
probabl
case
direct
specif
sarscov
addit
antisarscov
igg
detect
serum
peopl
close
contact
histori
sar
patient
suggest
occult
infect
sarscov
occur
rare
usual
human
be
develop
specif
igm
antibodi
earlier
igg
infect
microorgan
howev
base
elisa
also
use
studi
antisarscov
igg
igm
antibodi
almost
simultan
appear
patient
sera
li
et
al
therefor
antisarscov
igg
antibodi
detect
antisarscov
igm
measur
patient
sera
studi
sinc
genom
sarscov
sequenc
complet
marra
et
al
rota
et
al
rtpcr
use
wide
detect
viral
genom
clinic
specimen
sensit
method
rapid
diagnosi
sar
howev
posit
rate
earli
phase
diseas
gener
less
present
studi
sarscov
rna
detect
patient
first
day
onset
tabl
agreement
result
report
other
wu
et
al
appar
half
sar
patient
diagnos
earli
phase
base
detect
viral
genom
n
protein
coronaviru
form
viral
core
nucleocapsid
probabl
abund
compon
replic
sinc
transcript
viru
may
carri
nucleotid
n
gene
base
specif
monoclon
antibodi
n
protein
coronaviru
infecti
bronchiti
viru
detect
tracheal
smear
slice
trachea
chicken
infect
experiment
yagyu
ohta
like
n
protein
sarscov
also
abund
replic
sinc
n
protein
detect
easili
sarscov
cell
cultur
lysat
lau
et
al
featur
make
possibl
detect
n
protein
sarscov
rapid
diagnost
strategi
recent
report
sar
patient
detect
n
protein
sera
earli
stage
diseas
che
et
al
che
et
al
clinic
sampl
includ
nasopharyng
aspir
urin
stool
sampl
sar
patient
also
detect
n
protein
lau
et
al
present
studi
n
protein
test
consecut
sera
sar
patient
assay
base
specif
monoclon
antibodi
meantim
sarscov
rna
also
amplifi
sampl
nine
sera
patient
collect
day
onset
posit
n
protein
four
patient
posit
viral
rna
sera
collect
day
posit
n
protein
howev
posit
rate
sarscov
rna
tabl
fig
show
detect
rate
n
protein
viral
rna
antisarscov
igg
differ
time
onset
data
demonstr
detect
n
protein
appear
sensit
detect
viral
rna
specif
antibodi
earli
phase
although
sampl
number
studi
rel
small
gener
n
protein
viral
rna
circul
togeth
peripher
blood
sarscov
particl
thu
compon
detect
compar
rate
howev
detect
rate
n
protein
higher
viral
rna
like
current
rtpcr
sensit
enough
detect
low
concentr
sarscov
rna
inde
half
sar
patient
posit
viral
rna
wu
et
al
also
observ
present
studi
instabl
viral
rna
ineffici
extract
rna
unoptim
primer
potenti
exist
inhibitori
substanc
may
contribut
less
sensit
rtpcr
inde
sensit
rtpcr
may
improv
optim
reaction
condit
yam
et
al
sinc
n
protein
sarscov
share
low
homolog
nucleocapsid
protein
member
coronaviru
famili
marra
et
al
rota
et
al
monoclon
antibodi
direct
n
protein
sarscov
captur
n
protein
coronavirus
inde
case
antibodi
direct
n
protein
sarscov
recogn
nucleocapsid
protein
two
human
coronavirus
che
et
al
studi
healthi
blood
donor
neg
n
protein
sarscov
indic
assay
highli
specif
therefor
n
protein
detect
sera
sar
patient
deriv
sarscov
notabl
fourteen
sera
collect
day
onset
eight
posit
n
protein
none
posit
viral
rna
tabl
indic
n
protein
sarscov
tend
persist
circul
longer
viral
rna
chicken
infect
experiment
coronaviru
infecti
bronchiti
viru
n
protein
also
last
longer
viru
tracheal
smear
slice
trachea
yagyu
ohta
like
n
protein
degrad
easili
viral
rna
circul
sinc
n
protein
express
mammalian
cell
selfinteract
form
dimer
oligom
et
al
may
stabil
helic
structur
therefor
eclia
n
protein
detect
viral
maker
sar
patient
rtpcr
show
neg
recent
competit
elisa
base
two
monoclon
antibodi
sarscov
develop
berri
et
al
appear
sensit
current
indirect
elisa
detect
antisarscov
method
may
altern
rapidli
diagnos
sarscov
infect
comparison
eclia
use
studi
berri
et
al
elisa
identifi
sarscov
infect
remain
studi
conclus
although
number
patient
includ
present
studi
limit
data
demonstr
eclia
n
protein
sarscov
sensit
rtpcr
viral
rna
identifi
sarscov
infect
earli
stage
diseas
addit
eclia
advantag
avoid
special
expertis
timeconsum
procedur
crosscontamin
rtpcr
use
easili
clinic
laboratori
therefor
n
antigencaptur
eclia
promis
method
earli
diagnosi
sarscov
infect
